{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:11:15Z","timestamp":1790683875039,"version":"4.1.0"},"reference-count":42,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,3,2]],"date-time":"2015-03-02T00:00:00Z","timestamp":1425254400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"University of Toulouse and the Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:p>International guidelines on immune thrombocytopenia (ITP) management recommend vaccination against <jats:italic>Streptococcus pneumoniae<\/jats:italic> (<jats:italic>S.p<\/jats:italic>.), <jats:italic>Haemophilus influenza b<\/jats:italic> (Hib) and <jats:italic>Neisseiria meningitidis<\/jats:italic> (<jats:italic>N.m<\/jats:italic>.) before splenectomy. French guidelines also recommend these vaccinations before rituximab. The aim of this study was to assess the application of these recommendations. The French Adult ITP: a French pHarmacoepidemiological study (FAITH, n\u00b0ENCEPP 4574) is aimed at following in the French national health insurance system database (SNIIRAM) the cohort of all incident and persistent or chronic primary ITP adults treated in France. We assessed vaccine exposure in the 1,106 patients who entered the FAITH cohort between 2009 and 2011. Vaccination was said \u201crecommended\u201d if performed at least 2 weeks before rituximab or splenectomy accordingly with French guidelines. Among the 423 non\u2010splenectomized patients exposed to rituximab, vaccination rates against <jats:italic>S.p<\/jats:italic>., Hib and <jats:italic>N.m<\/jats:italic>. were respectively 32.4%, 18.9%, and 3.8%. It was recommended in 12.8%, 6.6%, and 1.2% of the patients, respectively. Among the 178 splenectomized patients, vaccination rates were 70.2%, 47.0%, and 11.9%, respectively (recommended: 60.1%, 35.7%, and 9.5%). Among the splenectomized patients previously exposed to rituximab (<jats:italic>n<\/jats:italic>\u2009=\u200967), 53.3% of the vaccinations occurred during the semester following a rituximab infusion that is during the maximal B\u2010cell depletion period. In multivariate analyses, a disease duration exceeding 3 months was the sole factor associated to recommended vaccination in rituximab\u2010treated patients as well as in splenectomized patients. This study stresses the need of better and earlier vaccination of ITP patients. Am. J. Hematol. 90:301\u2013305, 2015. \u00a9 2014 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.23930","type":"journal-article","created":{"date-parts":[[2014,12,30]],"date-time":"2014-12-30T06:02:44Z","timestamp":1419919364000},"page":"301-305","source":"Crossref","is-referenced-by-count":28,"title":["Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population\u2010based study in France"],"prefix":"10.1002","volume":"90","author":[{"given":"Guillaume","family":"Moulis","sequence":"first","affiliation":[{"name":"Service De M\u00e9decine Interne CHU De Toulouse Toulouse F\u201031000 France"},{"name":"Inserm UMR1027 Toulouse F\u201031000 France Universit\u00e9 De Toulouse III, UMR1027 Toulouse F\u201031000 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryse","family":"Lapeyre\u2010Mestre","sequence":"additional","affiliation":[{"name":"Inserm UMR1027 Toulouse F\u201031000 France Universit\u00e9 De Toulouse III, UMR1027 Toulouse F\u201031000 France"},{"name":"Service De Pharmacologie M\u00e9dicale Et Clinique CHU De Toulouse Toulouse F\u201031000 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Mah\u00e9vas","sequence":"additional","affiliation":[{"name":"Service De M\u00e9decine Interne Centre De R\u00e9f\u00e9rence Des Cytop\u00e9nies auto\u2010Immunes De L'adulte H\u00f4pital Henri Mondor Assistance Publique\u2010H\u00f4pitaux De Paris Universit\u00e9 Paris Est Cr\u00e9teil Cr\u00e9teil F\u201094000 France; Etablissement Fran\u00e7ais Du Sang Ile De France, Inserm U955, Cr\u00e9teil, H\u00f4pital Henri Mondor Paris F\u201094000 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Louis","family":"Montastruc","sequence":"additional","affiliation":[{"name":"Inserm UMR1027 Toulouse F\u201031000 France Universit\u00e9 De Toulouse III, UMR1027 Toulouse F\u201031000 France"},{"name":"Service De Pharmacologie M\u00e9dicale Et Clinique CHU De Toulouse Toulouse F\u201031000 France"},{"name":"Centre Midi\u2010Pyr\u00e9n\u00e9es De PharmacoVigilance De Pharmaco\u00e9pid\u00e9miologie Et D'informations Sur Le M\u00e9dicament CHU De Toulouse Toulouse F\u201031000 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Sailler","sequence":"additional","affiliation":[{"name":"Service De M\u00e9decine Interne CHU De Toulouse Toulouse F\u201031000 France"},{"name":"Inserm UMR1027 Toulouse F\u201031000 France Universit\u00e9 De Toulouse III, UMR1027 Toulouse F\u201031000 France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,3,2]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.01.026"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2009.11.020"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225565"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-302984"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-162503"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.1.3.3"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-578336"},{"key":"e_1_2_6_9_1","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Purpura thrombop\u00e9nique immunologique de l'enfant et de l'adulte. Protocole national de diagnostic et de soins.2009. Available at:http:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2009&-12\/ald_2_pnds_pti_imune_enft_adulte_web.pdf. Accessed on July 1 2014."},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-309153"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-582346"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.10.017"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-1168"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.07.044"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-8-200910200-00008"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.5.3684"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.54.3.214"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.075648"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-393975"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-494096"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-515478"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23580"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.08.036"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.2515\/therapie\/2014056"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.respe.2010.04.005"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.04.064"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.02.064"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12091"},{"key":"e_1_2_6_29_1","unstructured":"Vaccination schedule and recommendations from the \u201cHaut conseil de la sant\u00e9 publique\u201d in France 2009. Available at:http:\/\/www.invs.sante.fr\/beh\/2009\/16_17\/beh_16_17_2009.pdf. Accessed on July 1 2014."},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2011.06.004"},{"key":"e_1_2_6_32_1","first-page":"390","article-title":"An audit of the vaccination and antibiotic prophylaxis practices amongst patients splenectomised in lothian","volume":"58","author":"Pickering J","year":"2000","journal-title":"Health Bull (Edinb)"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/1096-8652(200009)65:1<25::AID-AJH4>3.0.CO;2-8"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/003655400458811"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-10-219"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-014-8597-x"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203313499959"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.3109\/09537104.2011.633179"},{"key":"e_1_2_6_39_1","unstructured":"Assurance Maladie. Vaccinations 2014. Available at:http:\/\/www.ameli-sante.fr\/vaccinations\/reaction-organisme-face-aux-virus.html. Accessed on July 1 2014."},{"key":"e_1_2_6_40_1","unstructured":"Arr\u00eat\u00e9 du 11 juillet 2012 relatif \u00e0 la mise en \u0153uvre du syst\u00e8me national d'information interr\u00e9gimes de l'assurance maladie. J Officiel de la R\u00e9publique Fran\u00e7aise 2012;0171:texte 10. Available at:http:\/\/www.legifrance.gouv.fr\/affichTexte.do?cidTexte=JORFTEXT000026221180&dateTexte=&categorieLien=id. Accessed on August 27 2013."},{"key":"e_1_2_6_41_1","unstructured":"J Officiel De La R\u00e9publique Fran\u00e7aise 2013 Arr\u00eat\u00e9 du 19 juillet 2013 relatif \u00e0 la mise en \u0153uvre du syst\u00e8me national d'information interr\u00e9gimes de l'assurance maladie"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.4.4.5437"},{"key":"e_1_2_6_43_1","unstructured":"Vaccination schedule and recommendations from the \u201cHaut conseil de la sant\u00e9 publique\u201d in France 2014. Available at:http:\/\/www.sante.gouv.fr\/IMG\/pdf\/Calendrier_vaccinal_ministere_sante_2014.pdf. Accessed on July 1 2014."}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23930","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23930","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23930","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T14:32:24Z","timestamp":1695565944000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.23930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,2]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1002\/ajh.23930"],"URL":"https:\/\/doi.org\/10.1002\/ajh.23930","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,2]]}}}